Chordia Therapeutics's gross profit for the
three
months ended in Aug. 2024 was 円-515.34 Mil. Chordia Therapeutics's gross profit for the trailing twelve months (TTM) ended in Aug. 2024 was 円-515.34 Mil.
Chordia Therapeutics had a gross margin of % for the quarter that ended in Aug. 2024 => No sustainable competitive advantage
During the past 4 years, the highestGross Margin % of Chordia Therapeutics was 20.13%. The lowest was 20.13%. And the median was 20.13%.
Chordia Therapeutics Gross Profit Historical Data
The historical data trend for Chordia Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chordia Therapeutics's Gross Profit
For the Biotechnology subindustry, Chordia Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordia Therapeutics's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Chordia Therapeutics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-515.34 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Chordia Therapeutics had a gross margin of % for the quarter that ended in Aug. 2024 => No sustainable competitive advantage
Chordia Therapeutics Gross Profit Related Terms
Thank you for viewing the detailed overview of Chordia Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:190A has been successfully added to your